|
|
 |
|
Viewing report
|
|
|
|
Therapeutic Vaccines for Cancer: On the Threshold of Success
Drug and Market Development Publishing, April 2005, Pages: 188
The authors combine expertise in market development with direct experience in cancer vaccine development to provide a concise analysis of this market including the current trends, and market forecast. This Report provides a comprehensive analysis of therapeutics currently in development, as well as those that have been discontinued. Development strategies are also discussed in detail. Primary market research was utilized to elucidate the opinions of cancer vaccine developers, and responses from these experts are included throughout the Report.
About the Author
Steven Bodovitz is a Principal at BioPerspectives, in San Francisco, California. He is an expert in markets and technologies related to drug and diagnostics discovery and development. He has been lead author or sole author on 14 comprehensive market and technology reports on topics ranging from angiogenesis inhibitors to proteomics to systems biology. He has written more than 15 business plans for start-up companies in fields ranging from cardiac implants to cell screening to protein biochips. He has published articles in Trends in Biotechnology, Drug Discovery Today and Drug Discovery World. He has presented his market and technology analyses at biotechnology conferences in the US, Europe, and Japan, and he has been quoted in Nature Biotechnology and The Economist. Prior to becoming an analyst, Dr. Bodovitz received his PhD in neuroscience from Northwestern University, where he studied the molecular mechanisms of Alzheimer's disease. Dirk Brockstedt is Associate Director of Cancer Vaccine Development at Cerus Corporation. He currently heads a research team working to identify and characterize novel vaccine strains derived from Listeria monocytogenes. In addition, he evaluates progress and opportunities throughout the entire field of cancer vaccines as part of his responsibility for internal and external research collaborations. Prior to Cerus, he led a research team at Aventis Gencell working to identify novel anti-angiogenic genes. In addition, he used in vitro and in vivo models for cancer to assess mechanisms of action of adenoviral-based immuno gene therapy. Prior to Aventis, he contributed to clinical studies at Stanford University, assessing the immuno-stimulatory efficacy of tumor-antigen pulsed dendritic cells administered via different routes. He has published multiple peer-reviewed articles and is an inventor of one issued and four submitted patents. Dr. Brockstedt received his PhD in immunology from the University of Kiel (Germany) for research primarily conducted at Stanford on the delivery of tumor antigens into the MHC class I pathway of antigen presenting cells.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Cancer Vaccines and Tumor Immunity
Therapeutic Cancer Vaccines: Evolving Strategies and Pipeline Prospects
Cancer Vaccine Developments to 2013 + Cancer Vaccine Tracker
Cancer Vaccine Developments to 2013
Therapeutic Vaccines: More Trials and Tribulations
Building Better Cancer Vaccines: The Progress and Promise of R&D
Cancer Vaccines: Measuring Market Potential
Analytical Tool - Cancer Vaccines
Outlook for Cancer Vaccine Development
Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines
Cancer Cell Therapy Markets
|
|
|
|
